

NeoVac Announces Dr. Jan Hendrik Egberts as Chief Executive Officer

London, UK — [NeoVac](#), a leading pharmaceutical company specializing in innovative lipid nanoparticle (LNP) technologies for mRNA therapeutics, is pleased to announce the appointment of Dr. Jan H. Egberts as Chief Executive Officer to guide the next phase of growth for the company.

Over the past four years, NeoVac has transformed from a scientific concept into a clinically validated platform poised for scale. Dr. Egberts brings a successful track record in biotech company leadership, including previous roles as CEO, board chair and investor across both private and publicly listed healthcare companies. His strategic and operational expertise will be instrumental as NeoVac enters its next stage of growth.

Egberts shared, “As one of the earliest investors in the company I have a long held belief in NeoVac’s vision for transforming RNA delivery through NeoVac’s proprietary LNP platform featuring clinically validated improved safety. I look forward to working closely with our exceptional team to accelerate development programs and expand global access to our technology.”

Egberts has over 25 years of experience in the pharmaceutical and medtech industries, most recently as the CEO of his own family office, Veritas Investment. Veritas Investments owns eight medical device and medical services companies throughout Europe as well as minority equity positions in more than 10 privately held healthcare companies. Dr Egberts is past chair of ViroClinics, (sold to Serba), Photocure ASP and Nordic Nanovector ASP. Dr Egberts currently serves on the supervisory Board of the European Nuclear Reactor Group for Medical Isotopes, NRG / Pallas as well as a number of privately held companies and foundations. Prior to Veritas Investments, Dr Egberts served as CEO of OctoPlus, which he sold to Dr Reddy’s, Agendia as well as an operating advisor for 3i Group. He graduated from Erasmus University Medical School in the Netherlands and obtained his MBA from Stanford, after which he worked as a management consultant for McKinsey.

NeoVac’s proprietary LNP platform addresses critical limitations of conventional delivery systems, offering tunable immune activation, tissue-specific targeting, high RNA payload capacity, and clinically validated enhanced safety via fully biodegradable materials. The company has also developed thermostable formulations that remain stable at room temperature, a major breakthrough for global vaccine distribution and accessibility.

###

About NeoVac

NeoVac is a clinical-stage biotechnology company revolutionizing RNA-based medicine through its proprietary lipid nanoparticle (LNP) platform. Designed for precision, improved safety, and scalability, NeoVac’s LNPs enable next-generation vaccines and RNA therapeutics across inflammation, oncology, gene editing, and infectious disease. The company is headquartered in Milton Park, Abingdon, UK, and is supported by a global team of scientific leaders and investors.